FINHUB Insights

VRTX · Q1 FY26 · Mar 31, 2026

Vertex Pharmaceuticals Q1 FY26: where the revenue came from and where it went

Vertex Pharmaceuticals Q1 FY26: revenue $3B (+8% year over year). Net profit $1B. Largest cohort TRIKAFTAKAFTRIO $2.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 5, 2026 10-Q
Sankey diagram of Vertex Pharmaceuticals's income statement for Q1 FY26: revenue of $3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3B +8% year over year
Gross profit$2.6B 87% margin
Operating profit$1.1B 38% margin
Net profit$1B 35% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 3 100% +8%
TRIKAFTAKAFTRIO 2.4 80% −7%
ALYFTREK 0.4 13% +687%
Manufactured Product Other 0.1 3% −12%
Cost of revenue−0.413%
Gross profit2.687% margin+0pp
SG&A−0.517%+2pp
Other−132%+0pp
Operating profit1.138% margin+15pp
Tax−0.2
Net profit135%+11pp
Filing on EDGAR More quarters of VRTX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters